The Ethics of Personalised Medicine

Name: The Ethics of Personalised Medicine | Critical Perspectives
Brand: Ashgate Publishing Limited
Price: 103.99 EUR
Availability: OnlineOnly

Critical Perspectives

Jan Schildmann Sebastian Waescher Verena Sandow Jochen Vollmann(Herausgeber*in)

Ashgate Publishing Limited

Erschienen am 1. Juni 2015

314 Seiten

E-Book

PDF mit Adobe-DRM

Systemvoraussetzungen

978-1-4724-4797-5 (ISBN)

103,99 €inkl. 7% MwSt.

Systemvoraussetzungen

für PDF mit Adobe-DRM

E-Book Einzellizenz

Als Download verfügbar

Beschreibung

In recent times, the phrase `personalised medicine' has become the symbol of medical progress and a label for better health care in the future. However, a controversial debate has developed around whether these promises of better, more personal and more cost-efficient medicine are realistic. This book brings together leading researchers from across Europe and North America, from both normative and empirical disciplines, who take a more critical view of the often encountered hype associated with personalised medicine. Partially drawing on a four year collaborative research project funded by the German Ministry for Education and Research, the book presents a multidisciplinary debate on the current state of research on the ethical, legal and social implications of personalised medicine. At a time when future health care is a topic of much discussion, this book provides valuable policy recommendations for the way forward.

This study will be of interest to researchers from various disciplines including philosophy, bioethics, law and social sciences.

Rezensionen / Stimmen

`This volume is a landmark for demythologising the buzzword "personalised medicine", critically differentiating between hype and false hopes on the one hand and realistic approaches and outlooks on the other. By comprehensively comprising a wide range of excellent normative and empirical studies, it empowers anyone interested in better understanding the presuppositions and consequences of the term "personalised medicine" to form a well-informed judgement on one of the most augured ideas in cutting-edge medicine.'
Peter Dabrock, University of Erlangen, Germany, and Vice Chair of the German Ethics Council and member of the European Group on Ethics in Science and New Technologies (EGE)

'The concept "personalised medicine" has become a buzz word in contemporary medicine. However, it is not at all clear what the concept entails. The suggestion is that treatment will be adapted to the individual patient. Yet, the basis is not knowledge of the individual patient, but statistical analysis of characteristics of patient groups. Moreover, individual patient wishes and preferences may become less relevant, if treatment options are seen in terms of chances of patient groups. This book contains critical discussions of the concept of "personalised medicine", both from an empirical and a normative perspective. It provides a timely and needed contribution to the debate.'
Guy Widdershoven, VU University Medical Center, Netherlands

`Gathering together a broad range of academics working in this important area, this book considers comprehensively the conceptual, ethical and practical issues associated with the ethics of personalised medicine. The editors are to be congratulated on this volume and for the way in which it carefully reflects on the issues involved in personalised medicine and its application in practice.'
Mark Sheehan, University of Oxford, UK

Weitere Details

Weitere Ausgaben

Personen

Inhalt

Contents: Introduction, Jochen Vollmann, Verena Sandow, Sebastian Waescher and Jan Schildmann. Part I Personalised Medicine - Medicine for the Person? Concepts and Contextual Aspects: What is personalised medicine? Sharpening a vague term based on a systematic literature review, Sebastian Schleidgen, Corinna Klingler, Teresa Bertram, Wolf H. Rogowski and Georg Marckmann; Alarming symptoms of a paradigm shift? An approach to bridge the gap between hypothetical ethics and the current status of individualised medicine research, Tobias Fischer, Marcus Doerr, Robin Haring and Martin Langanke; Personalised medicine: getting past the controversies, George P. Browman; Patient as person in personalised medicine: autonomy, responsibility and the body, Thomas Wabel; The authority of corporeality and emotions: the new phenomenology and its relevance to the German debate on personalised medicine, Mathias Wirth; Towards integration of `personalised' and `person-centred' medicine: the concept of `integrative and personalised health care', Peter Heusser. Part II Personalised Medicine in Clinical and Practical Research: Ethical considerations for developing a best-practice guideline for next generation sequencing in oncology, Eva C. Winkler, Klaus Tanner, Hanno Glimm and Christof von Kalle; Practice variation across consent templates for biobank research: a survey of German biobanks, Irene Hirschberg, Hannes Kahrass and Daniel Strech; Individualised medicine in the diagnosis and prognosis of patients younger than 65 years with normal karyotype acute myeloid leukemia: a systematic review and meta-analysis of the impact of Fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD), Matthias Port, Miriam Boettcher, Felicitas Thol, Nicole Trachte, Juergen Wasem, Arnold Ganser, Laura Pouryamout and Anja Neumann; Taking it personally: patients' perspectives on personalised medicine and its ethical relevance, Sabine Woehlke, Julia Perry and Silke Schicktanz; `Personalised medicine' in oncology: physicians' perspectives on contributions to and challenges for clinical practice, Sebastian Waescher, Jan Schildmann, Caroline Brall and Jochen Vollmann; Through thick and big: data-rich medicine in the era of personalisation, Barbara Prainsack. Part III Personalised Medicine in Health-Care Systems: Benefit assessment of personalised interventions: methodological challenges and approaches to a solution, Juergen Windeler and Stefan Lange; The relevance of the analytic validity of genetic biomarker tests in personalised medicine in oncology, Franz Hessel; Approval and reimbursement of personalised drugs: interim results of the adjustment process, Michael Noweski, Anke Walendzik, Franz Hessel, Rebecca Jahn and Juergen Wasem; Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?, Wolf H. Rogowski, Scott D. Grosse, Joerg Schmidtke and Georg Marckmann; Personalised medicine as orphan drugs? Legal and ethical questions, Sina Gottwald and Stefan Huster; Personalised medicine: priority setting and opportunity costs in European public health-care systems, Jochen Vollmann. Part IV Personalised Medicine in Oncology: Recommendations for Future Development: `Personalised medicine': multidisciplinary perspectives and interdisciplinary recommendations on a framework for future research and practice, Jan Schildmann, Miriam Boettcher, Maria Gabriel, Arnold Ganser, Sina Gottwald, Franz Hessel, Stefan Huster, Rebecca Jahn, Anja Neumann, Michael Noweski, Matthias Port, Laura Pouryamout, Verena Sandow, Felicitas Thol, Sebastian Waescher, Anke Walendzik, Juergen Wasem and Jochen Vollmann. Index.

Systemvoraussetzungen

Als PDF speichern Als Link merken